(Q43074797)

13 November 2017

title

Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. (English)

1 reference

13 November 2017

1 reference

1 reference

Salvador Cabrera Figueroa

1

1 reference

13 November 2017

Alicia Iglesias Gómez

2

1 reference

13 November 2017

Almudena Sánchez Martín

3

1 reference

13 November 2017

María de la Paz Valverde Merino

4

1 reference

13 November 2017

Alfonso Domínguez-Gil Hurlé

5

1 reference

13 November 2017

Miguel Cordero Sánchez

6

1 reference

13 November 2017

publication date

1 January 2010

1 reference

Clinical Drug Investigation

13 November 2017

published in

1 reference

13 November 2017

volume

30

1 reference

13 November 2017

issue

6

1 reference

13 November 2017

page(s)

405-411

1 reference

Central nervous system adverse effects with efavirenz: case report and review

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Higher efavirenz plasma levels correlate with development of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Clinical impact of patient population differences and genomic variation in efavirenz therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Hyperhidrosis in association with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256910

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20441246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20441246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20441246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/BF03256910

1 reference

13 November 2017

1 reference